IQVIA Holdings, Inc. (IQV) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Sell if holding. Multiple concerning factors at $173.18: Leverage penalty (D/E 2.6): -1.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.5).
IQVIA is a global provider of clinical research services, commercial intelligence, and healthcare analytics to life sciences and healthcare clients, with ~93,000 employees in 100+ countries. It operates through Technology & Analytics Solutions, Research & Development Solutions,... Read more
Sell if holding. Multiple concerning factors at $173.18: Leverage penalty (D/E 2.6): -1.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.5). Chart setup: Death cross but MACD improving, RSI 71. Score 5.6/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 62d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent Developments — IQVIA Holdings, Inc.
Latest news
- A Look At IQVIA Holdings (IQV) Valuation After ESOP Linked Shelf Registration For Potential Share Issuance - Yahoo Finan — Yahoo Finance neutral
- IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? - Yahoo Finance — Yahoo Finance positive
- Vanguard Group Inc. Acquires 159,899 Shares of IQVIA Holdings Inc. $IQV - MarketBeat — MarketBeat positive
- IQVIA Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation (NYSE:IQV) 2026-05-05 - Seeking Alpha — Seeking Alpha neutral
- IQVIA Holdings Inc Stock (IQV) Closed Up by 9.60% on May 5: Key Drivers Unveiled - TradingKey — TradingKey positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-23Item 5.02LOWStockholders approved the 2026 Incentive and Stock Award Plan at the April 23, 2026 Annual Meeting, increasing reserved shares by 5M (to 125.35M total), extending plan term to January 29, 2036, and specifying change-of-control award treatment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $173.18: Leverage penalty (D/E 2.6): -1.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.5). Chart setup: Death cross but MACD improving, RSI 71. Prior stop was $161.06. Score 5.6/10, moderate confidence.
Take-profit target: $205.74 (+18.8% upside). Prior stop was $161.06. Stop-loss: $161.06.
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.5); Leverage penalty (D/E 2.6): -1.5.
IQVIA Holdings, Inc. trades at a P/E of 21.5 (forward 12.2). TrendMatrix value score: 7.5/10. Verdict: Sell.
31 analysts cover IQV with a consensus score of 4.2/5. Average price target: $229.
What does IQVIA Holdings, Inc. do?IQVIA is a global provider of clinical research services, commercial intelligence, and healthcare analytics to life...
IQVIA is a global provider of clinical research services, commercial intelligence, and healthcare analytics to life sciences and healthcare clients, with ~93,000 employees in 100+ countries. It operates through Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions segments; no single client exceeded 10% of revenue in 2025.